ponatinib

Ligand id: 5890

Name: ponatinib

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ponatinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 65.77
Molecular weight 532.22
XLogP 6.33
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

References
1. Dale T, Clarke PA, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz MJ, Mallinger A, Samant RS, Czodrowski P, Musil D et al.. (2015)
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Nat. Chem. Biol.11 (12): 973-80. [PMID:26502155]
2. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S et al.. (2010)
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
J. Med. Chem.53 (12): 4701-19. [PMID:20513156]
3. Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C. (2013)
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mol. Cell. Endocrinol.377 (1-2): 1-6. [PMID:23811235]
4. Willemsen-Seegers N, Uitdehaag JC, Prinsen MB, de Vetter JR, de Man J, Sawa M, Kawase Y, Buijsman RC, Zaman GJ. (2016)
Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.
J. Mol. Biol.,  [Epub ahead of print]. [PMID:28043854]